Dipeptidyl peptidase III in malignant and non-malignant gynaecological tissue

European Journal of Cancer

Volumn 34, Issue 3, 1998, Pages 399-405

  Simaga S ^a   Babic D ^b   Osmak, M ^a   Ilic Forko J ^b   Vitale, Lj ^a   Milicic D ^b   Abramic M ^a,c  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Dipeptidyl peptidase III; Endometrial cancer; Human ovary; Human uterus; Ovarian cancer

Indexed keywords

DIPEPTIDYL PEPTIDASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; ENDOMETRIUM CANCER; ENZYME ACTIVITY; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TERATOMA; PRIORITY JOURNAL; UTERUS MYOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; DIPEPTIDYL PEPTIDASES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 0032005572     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00401-2     Document Type: Article

References (45)

1. 1. Torres-Rosado A, O'Shea KS, Tsuji A, Chou S-H, Kurachi K. Hepsin, a putative cell-surface protease, is required for mammalian cell growth. Proc Natl Acad Sci USA 1993, 90, 7181-7185.
2. 2. Pagano M, Tam SW, Theodoras AM, et al. Role of ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269, 682-685.
3. 3. Miura M, Zhu H, Rotello R, Hartwieg EA, Yuan J. Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 1993, 75, 653-660.
4. 4. Wigler M, Weinstein IB. Tumor promoter induces plasminogen activator. Nature 1976, 259, 232-233.
5. 5. Billings PC, Carew JA, Keller-McGandy CE, Goldberg AL, Kennedy AR. A serine protease activity in C3H/10T1/2 cells that is inhibited by anticarcinogenic protease inhibitors. Proc Natl Acad Sci USA 1987, 84, 4801-4805.
6. 6. Himelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW, Muschel RJ. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 1994-5, 14, 246-258.
7. 7. Vasishta A, Baker PR, Hopwood D, Holley PM, Cushieri A. Proteinase-like peptidase activities in malignant and non-malignant gastric tissue. Br J Surg 1985, 72, 386-388.
8. 8. Sivaparvathi M, Sawaya R, Wang SW, et al. Overexpression and localization of cathepsin B during the progression of human gliomas. Clin Exp Metastasis 1995, 13, 49-56.
9. 9. Stetler-Stevenson WG, Liotta LA, Kleiner DE, Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 1993, 7, 1434-1441.
10. 10. Temparis S, Asensi M, Taillandier D, et al. Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats. Cancer Res 1994, 54, 5568-5573.
11. 11. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985, 44, 139-266.
12. 12. Rochefort H. Biological and clinical significance of cathepsin D in breast cancer. Acta Oncol 1992, 31, 125-130.
13. 13. Lah TT, Kokalj-Kunovar M, Štrukelj B, et al. Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer 1992, 50, 36-44.
14. 14. Constam DB, Tobler AR, Rensing-Ehl A, Kemler I, Hersh LB, Fontana A. Puromycin-sensitive aminopeptidase: sequence analysis, expression, and functional characterization. J Biol Chem 1995, 270, 26931-26939.
15. 15. Saiki I, Fujii H, Yoneda J, et al. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 1993, 54, 137-143.
16. 16. McDonald JK, Barrett AJ, eds. Mammalian Proteases: A Glossary and Bibliography, Vol. 2: Exopeptidases. London, Academic Press, 1986, 111-144.
17. 17. Vitale Lj, Zubanović M, Abramić M. Properties and distribution of aminopeptidase and dipeptidyl aminopeptidase III of human erythrocytes. Acta Biol Med Germ 1981, 40, 1489-1495.
18. 18. Shimamori Y, Watanabe Y, Fujimoto Y. Purification and characterization of dipeptidyl aminopeptidase III from human placenta. Chem Pharm Bull 1986, 34, 3333-3340.
19. 19. Ellis S, Nuenke JM. Dipeptidyl arylamidase III of the pituitary: purification and characterization. J Biol Chem 1967, 242, 4623-4629.
20. 20. Kecorius E, Small DH, Livett BG. Characterization of a dipeptidyl aminopeptidase from bovine adrenal medulla. J Neurochem 1988, 50, 38-44.
21. 21. Lee C-M, Snyder SH. Dipeptidyl-aminopeptidase III of rat brain: selective affinity for enkephalin and angiotensin. J Biol Chem 1982, 257, 12043-12050.
22. 22. Vanha-Pertulla T. Dipeptidyl peptidase III and alanyl amino-peptidase in the human seminal plasma: origin and biochemical properties. Clin Chim Acta 1988, 177, 179-196.
23. 23. Abramić M, Zubanović M, Vitale Lj. Dipeptidyl peptidase III from human erythrocytes. Biol Chem Hoppe-Seyler 1988, 369, 29-38.
24. 24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein, utilizing the principle of protein-dye binding. Anal Biochem 1976, 72, 248-254.
25. 25. Hu JG, Yokoyama T, Kitagawa T. Studies on the optimal immunization schedule of experimental animals. V. The effects of the route of injection, the content of Mycobacteria in Freund's adjuvant and the emulsifying antigen. Chem Pharm Bull 1990, 38, 1961-1965.
26. 26. Kurstak E. Preparation of immunoglobulins, antibodies, or Fab fragments. In Kurstak E, ed. Enzyme Immunodiagnosis. Orlando, Florida, Academic Press, 1986, 5-12.
27. 27. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227, 680-685.
28. 28. Hempelmann E, Kaminsky R. Long term stability of colors after silver staining. Electrophoresis 1986, 7, 481.
29. 29. Imai K, Maeda M, Fujiwara H, et al. Human endometrial stromal cells and decidual cells express cluster of differentiation (CD)13 antigen/aminopeptidase N and CD10 antigen/neutral endopeptidase. Biol Reprod 1992, 46, 328-334.
30. 30. Imai K, Maeda M, Fujiwara H, et al. Dipeptidyl peptidase IV as a differentiation marker of the human endometrial glandular cells. Human Reprod 1992, 7, 1189-1194.
31. 31. Tanaka T, Umeki K, Yamamoto I, Sakamoto F, Noguchi S, Ohtaki S. CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma. Int J Cancer 1995, 64, 326-331.
32. 32. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexa-peptide angiotensin IV. J Clin Invest 1995, 96, 2515-2520.
33. 33. Schatz F, Aigner S, Papp C, Toth-Pal E, Hausknecht V, Lockwood CJ. Plasminogen activator activity during decidualization of human endometrial stromal cells is regulated by plasminogen activator inhibitor 1. J Clin Endocrinol Metab 1995, 80, 2504-2510.
34. 34. Pappot H, Gaardsvoll H, Rømer J, et al. Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol Chem Hoppe-Seyler 1995, 376, 259-267.
35. 35. Pujade-Lauraine E, Lu H, Mirshahi S, et al. Plasminogen-activation system in ovarian tumors. Int J Cancer 1993, 55, 27-31.
36. 36. Kuhn W, Pache L, Schmalfeldt B, et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 1994, 55, 401-409.
37. 37. Palumbo A, Carcangiu ML, Roa L, Pepperell J, Pourmotabbed G, Naftolin F. The ovarian renin-angiotensin system in poly-cystic ovarian syndrome. Ann N Y Acad Sci 1993, 687, 39-45.
38. 38. Squires PM, Kennedy TG. Evidence for a role for a uterine renin-angiotensin system in decidualization in rats. J Reprod Fert 1992, 95, 791-802.
39. 39. Marbaix E, Kokorine I, Donnez J, Courtoy PJ, Eeckhout Y. Collagenases et metalloproteases apparentees: un rôle essentiel dans le declenchement de la menstruation? Medecine/Sciences 1995, 11, 1261-1269.
40. 40. Takemura M, Azuma C, Kimura T, et al. Malignant cell-specific gelatinase activity in human endometrial carcinoma. Cancer 1992, 70, 147-151.
41. 41. Nazeer T, Malfetano JH, Rosano TG, Ross JS. Correlation of tumor cytosol cathepsin D with differentiation and invasiveness of endometrial adenocarcinoma. Anat Pathol 1992, 97, 764-769.
42. 42. Sanfilippo JS, Miseljic S, Yang A-R, Doering DL, Shaheen RM, Wittliff JL. Quantitative analysis of epidermal growth factor receptors, HER-2/neu oncoprotein and cathepsin D in non-malignant and malignant uteri. Cancer 1996, 77, 710-716.
43. 43. Osmak M, Babić D, Abramić M, Vrhovec I, Miličić D, Škrk J. Cathepsin D content in malignant tumours of corpus uteri. Eur J Cancer 1997, 33, 699-700.
44. 44. Hakala A, Kacinski BM, Stanley ER, et al. Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: comparison with CA 125 and the aminoterminal propeptide of type III procollagen. Am J Obstet Gynecol 1995, 173, 112-119.
45. 45. Hashholzner U, Baumgartner L, Stieber P, Meier W, Hofmann K, Fateh-Moghadam A. Significance of the tumor markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma. Anticancer Res 1994, 14, 2743-2746.